4,4-二甲基-delta(8)-胆甾烯醇 | 7240-15-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 4,4-二甲基-delta(8)-胆甾烯醇
• 英文名称: 4,4-Dimethylcholest-8-ene-3β-ol
• 英文别名: 4,4-Dimethyl-delta(8)-cholestenol；(3S,10S,13R,14R,17R)-4,4,10,13-tetramethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol
• CAS: 7240-15-5
• 化学式: C₂₉H₅₀O
• 分子量: 414.715
• InChiKey: FYHRVINOXYETMN-LCHSQBAESA-N

物化性质

• 熔点：
  157-159 °C(Solv: ethyl ether (60-29-7); methanol (67-56-1))
• 沸点：
  492.9±44.0 °C(Predicted)
• 密度：
  0.97±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,4-二甲基-delta(8)-胆甾烯醇 在 palladium-carbon 溶剂黄146 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 4,4-Dimethylcholest-8(14)-ene-3β-ol
  参考文献：
  名称：

  Regulation of meiosis using sterols

  摘要：

  本发明涉及某些甾醇衍生物作为药物的用途。

  公开号：

  US05716777A1
• 作为产物：
  描述：

  二异丁基氢化铝 、 Rochelle's salt 以 乙醚 、 二氯甲烷 、 水 为溶剂， 生成 4,4-二甲基-delta(8)-胆甾烯醇
  参考文献：
  名称：

  Regulation of meiosis using sterols

  摘要：

  本发明涉及某些甾醇衍生物作为药物的用途。

  公开号：

  US05716777A1

文献信息

• Meiosis regulating compounds
  申请人：——

  公开号：US20020013302A1

  公开（公告）日：2002-01-31

  Sterol derivative compounds, structurally related to natural compounds which can be extracted from bull testes and from human follicular fluid, useful for regulating meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives.

  甾醇衍生物化合物，结构上与可以从公牛睾丸和人类卵泡液中提取的天然化合物相关，对调节卵母细胞和男性生殖细胞中的减数分裂有用。其中一些化合物对治疗不孕症有用，而其他化合物则可用作避孕药。
• Regulation of meiosis
  申请人：——

  公开号：US20030004148A1

  公开（公告）日：2003-01-02

  Compounds of Formula I and methods of regulating the meiosis in a mammalian germ cell which method comprises administering an effective amount of the compound of Formula I to a germ cell in need of such a treatment.

  公式I的化合物和调控哺乳动物生殖细胞减数分裂的方法，所述方法包括向需要此类治疗的生殖细胞中施用公式I的化合物的有效量。
• Compositions for the treatment of cataracts
  申请人：Catacore, Inc.

  公开号：US10398709B2

  公开（公告）日：2019-09-03

  In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ7,24-cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-OSO3H (5-cholesten-3β,25-sulfate), 5-cholesten-3β-OSO3H,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.

  在一个实施方案中，本申请公开了一种用于治疗眼部疾病、病变和损伤的水性眼科组合物，该组合物包括a) 一种类固醇，或至少两种类固醇的组合，选自由羊毛甾醇、二氢羊毛甾醇、4,4-二甲基胆甾-8(9),14,24-三烯-3β-醇、4,4-二甲基胆甾-8,24-二烯-3β-醇、4,4-二甲基胆甾-8-烯-3β-醇组成的组、4,4-二甲基胆甾烯-8(9),14-二烯-3β-醇、14-去甲基羊毛甾醇、羊毛甾醇、Δ7,24-胆甾烯醇、胆固醇、胆甾-7-烯醇、胆固醇酯、7-脱氢胆固醇、去甾醇、7-脱氢去甾醇、去甾醇、27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-OSO3H (5-cholesten-3β,25-sulfate), 5-cholesten-3β-OSO3H,25-ol (5-cholesten-3β-sulfate. 25-ol), 5-cholesten-3β-Sulfate、25-醇）、5-胆甾烯-3β,25-二醇、二硫酸盐和它们的酯，或它们的药学上可接受的盐，其浓度对治疗和/或预防眼病、病变和损伤有效；b) 药用辅料；以及使用此类组合物的治疗方法。
• Materials and methods relating to cholesterol biosynthesis enzymes
  申请人：Children's Hospital, Inc.

  公开号：US20020172956A1

  公开（公告）日：2002-11-21

  The present invention relates to the identification of the NSDHL gene product as a 3&bgr;-HSD participating in the conversion of 4,4-dimethylcholest-8(9)-en-3&bgr;-ol to cholest-8(9)-en-3&bgr;-ol in the cholesterol and vitamin D biosynthetic pathway. Based upon this function the present invention contemplates methods for manipulating the biosynthetic pathway at the step of involvement of NSDHL to increase or decrease the levels of cholesterol and/or vitamin D (or downstream products such as steroids) produced by a cell. Also contemplated are methods for manipulating the accumulation of intermediate compounds upstream of the step of NSDHL in the pathway. Diagnostic methods involving identification of mutations in the genes encoding enzymes involved in the conversion of 4,4-dimethylcholest-8(9)-en-3&bgr;-ol to cholest-8(9)-en-3&bgr;-ol are also provided, as well as diagnostic methods involving detection of abnormal accumulation of sterol intermediates prior to generation of choles-8(9)-en-3&bgr;-ol in the pathway.

  本发明涉及将 NSDHL 基因产物鉴定为 3&bgr;-HSD 参与胆固醇和维生素 D 生物合成途径中 4,4-二甲基胆甾-8(9)-烯-3&bgr;-醇向胆甾-8(9)-烯-3&bgr;-醇的转化。基于这一功能，本发明考虑了在 NSDHL 参与的步骤中操纵生物合成途径的方法，以提高或降低细胞产生的胆固醇和/或维生素 D（或下游产物，如类固醇）的水平。此外，还考虑采用一些方法来控制途径中 NSDHL 步骤上游中间化合物的积累。还提供了涉及鉴定编码参与将 4,4-二甲基胆甾-8(9)-烯-3&bgr;-醇转化为胆甾-8(9)-烯-3&bgr;-醇的酶的基因突变的诊断方法，以及涉及检测途径中胆甾-8(9)-烯-3&bgr;-醇生成之前甾醇中间产物异常积累的诊断方法。
• STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS
  申请人：NOVO NORDISK A/S

  公开号：EP0767798B1

  公开（公告）日：2003-09-03